Objectives:

• Effectively managing solar energy collected over the weekends when the factory’s electric demand is low.
• To find a solution to manage those excess solar energies for further utilisation.

Desired Outcomes:

• Real users are from the Toyota Manufacturing plants in each country.
• The primary outcome is to be sustainable and have good excess energy management, which will, in turn, lead to cost reduction.

Current Limitation:

• No means to manage the loss of energy, which means lost cost.

About the Problem Statement:

One of the future growth pillars for Mitsubishi Chemical Holdings Corporation’s (MCHC) healthcare business is to provide ‘around the pill solutions’ enabled by digital technology, intended to improve the quality of life of patients and their families, in their core therapeutics areas. Therapeutics areas of interest include the central nervous system (especially neuromuscular disease), autoimmune diseases and metabolic diseases.

Objectives:

To establish multiple touchpoints with patients during the patient journey from prevention to prognosis, to collect and analyse healthcare data and expand the value of current treatments.

Examples of such solutions could be digital platforms enabling patient-centric disease management, electronic patient-reported outcomes, digital diagnostics, disease tracking, digital medication management, digital biomarker, etc.

Objective:

• To achieve zero CO2 emission by having a solution for an oven that can bake the vehicle and not emit CO2, e.g. electricity or others.

Desired Outcomes:

• Real users are from the Toyota Manufacturing plants in each country.
• The main outcome is to be sustainable and achieving zero CO2 emission as part of company policy.

Current Limitation:

• Currently, the burners are still using gas, thus resulting in a high volume of CO2 emissions.

To automate this highly manual process & improve the standardisation & visibility of the booking process.

About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions to treat neurological diseases in the Japanese population.

Hardware MedTech startups for neuromodulation and software startups experience in healthcare for a mobile app would be relevant.

Objectives:

To save and reduce patients with neurological diseases relating to the central nervous system, including psychiatric and neurodegenerative diseases. Solution examples include user-friendly therapeutic modalities like non-invasive neuromodulation and/or digital therapeutics at home.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).

Objective:

• To get some tools that can gather the data/visualise current stock condition and price for further ordering decision-making.

Desired Outcomes:

• Real users are from the Toyota Manufacturing plants in each country, but in using this tool, TDEM R-HQ can also utilise it.
• The primary outcome is to attain cost reduction.
• The tool should help gather data or visualise current stock conditions and prices for further ordering decision-making.

Current Limitation:

• Currently, there is no visualisation of the data and no centralised tool to do so.

About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions for the ageing population to correctly understand their own health conditions.

Startups with capabilities to develop AI algorithms based on health / vital data for chronic diseases and startups with technologies for sensing vital signals for chronic diseases would be relevant.

Objectives:

To provide an easy solution for the ageing population with chronic diseases to proactively understand their own health conditions from the patients’ homes. This includes, but should not be limited to, innovative technology to predict exacerbation before their illness gets worse.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).